Guest: Rozalina G. McCoy, MD, MS <br>


  <p>Dr. Rozalina G. McCoy, an endocrinologist, primary care physician, and a National Institutes of Health-funded health services researcher examines hypoglycemia risk in insulin-treated type 2 diabetic patients and explores strategies to reduce their risk of recurrent hypoglycemia. </p>

Guest: Rozalina G. McCoy, MD, MS Dr. Rozalina G. McCoy, an endocrinologist, primary care physician, and a National Institutes of Health-funded health services researcher examines hypoglycemia risk in insulin-treated type 2 diabetic patients and explores strategies to reduce their risk of recurrent hypoglycemia.

Key Pathways to Reducing Recurrent Hypoglycemia Risk in Patients with Insulin-Treated T2D

As the number of Americans living with diabetes continues to rise, staying up to date on the latest diabetes research is more essential than ever to help patients achieve glucose control. With Diabetes Discourse, you’ll hear from diabetes and endocrinology experts on emerging research, diagnostic and treatment strategies, and various elements that impact a patient’s disease course, including risk factors, vitamin and mineral supplementation, physical activity, and kidney disease.
Because when it comes to diabetes, glucose control is just the beginning.

Medicine

As the number of Americans living with diabetes continues to rise, staying up to date on the latest diabetes research is more essential than ever to help patients achieve glucose control. With Diabetes Discourse, you’ll hear from diabetes and endocrinology experts on emerging research, diagnostic and treatment strategies, and various elements that impact a patient’s disease course, including risk factors, vitamin and mineral supplementation, physical activity, and kidney disease. Because when it comes to diabetes, glucose control is just the beginning.

Share Key Pathways to Reducing Recurrent Hypoglycemia Risk in Patients with Insulin-Treated T2D

Sign up to save your podcasts

Key Pathways to Reducing Recurrent Hypoglycemia Risk in Patients with Insulin-Treated T2D

Key Pathways to Reducing Recurrent Hypoglycemia Risk in Patients with Insulin-Treated T2D